

programs, personnel, and operations of the Commission including under 5 U.S.C. appendix 3; or (ii) by U.S. government employees and contract personnel,² solely for cybersecurity purposes. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.³

This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of §§ 201.10 and 210.8(c) of the Commission's Rules of Practice and Procedure (19 CFR 201.10, 210.8(c)).

By order of the Commission.

Issued: July 16, 2021.

Katherine Hiner,

Acting Secretary to the Commission.

[FR Doc. 2021-15553 Filed 7-21-21; 8:45 am]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-372]

Exempt Chemical Preparations Under the Controlled Substances Act

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Order with opportunity for comment.

SUMMARY: The applications for exempt chemical preparations received by the Drug Enforcement Administration (DEA) between September 1, 2020, and March 31, 2021, as listed below, were accepted for filing and have been approved or denied as indicated.

DATES: Interested persons may file written comments on this order in accordance with 21 CFR 1308.23(e). Electronic comments must be submitted, and written comments must be postmarked, on or before September 20, 2021. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.

ADDRESSES: To ensure proper handling of comments, please reference "Docket No. DEA-372" on all correspondence, including any attachments.

Electronic comments: DEA encourages that all comments be submitted through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment

field on the web page or to attach a file for lengthier comments. Please go to <http://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon completion of your submission you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on *Regulations.gov*. If you have received a comment tracking number, your comment has been successfully submitted and there is no need to resubmit the same comment.

Paper comments: Paper comments that duplicate the electronic submission are not necessary and are discouraged. Should you wish to mail a comment *in lieu of* an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

FOR FURTHER INFORMATION CONTACT: Terrence L. Boos, Ph.D., Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrisette Drive, Springfield, Virginia 22152; Telephone: (571) 362-8201.

SUPPLEMENTARY INFORMATION:

Posting of Public Comments

Please note that all comments received are considered part of the public record and made available for public inspection online at <http://www.regulations.gov> and in the DEA's public docket. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter. The Freedom of Information Act applies to all comments received.

If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "PERSONAL IDENTIFYING INFORMATION" in the first paragraph of your comment. You must also place all the personal identifying information you do not want posted online or made available in the public docket in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "CONFIDENTIAL BUSINESS INFORMATION" in the first paragraph of your comment. You must also

prominently identify confidential business information to be redacted within the comment.

Comments containing personal identifying information and confidential business information identified as directed above will generally be made publicly available in redacted form. If a comment has so much confidential business information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments posted to <http://www.regulations.gov> may include any personal identifying information (such as name, address, and phone number) included in the text of your electronic submission that is not identified as directed above as confidential.

An electronic copy of this document is available at <http://www.regulations.gov> for easy reference.

Legal Authority

Section 201 of the Controlled Substances Act (CSA) (21 U.S.C. 811) authorizes the Attorney General, by regulation, to exempt from certain provisions of the CSA certain compounds, mixtures, or preparations containing a controlled substance, if he finds that such compounds, mixtures, or preparations meet the requirements detailed in 21 U.S.C. 811(g)(3)(B).¹ DEA regulations at 21 CFR 1308.23 and 1308.24 further detail the criteria by which DEA's Assistant Administrator may exempt a chemical preparation or mixture from certain provisions of the CSA. The Assistant Administrator may, pursuant to 21 CFR 1308.23(f), modify or revoke the criteria by which exemptions are granted and modify the scope of exemptions at any time.

Exempt Chemical Preparation Applications Submitted Between September 1, 2020, and March 31, 2021

The Assistant Administrator received applications between September 1, 2020, and March 31, 2021, requesting exempt chemical preparation status detailed in 21 CFR 1308.23. Pursuant to the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23, the Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart I below is intended for laboratory, industrial, educational, or special research purposes and not for general administration to a human being or animal and either: (1) Contains no

¹ This authority has been delegated from the Attorney General to the Administrator of the DEA by 28 CFR 0.100, and subsequently redelegated to the Deputy Assistant Administrator pursuant to 28 CFR 0.104 and Section 7 of the appendix to subpart R of part 0.

² All contract personnel will sign appropriate nondisclosure agreements.

³ Electronic Document Information System (EDIS): <https://edis.usitc.gov>.

narcotic controlled substance and is packaged in such a form or concentration that the packaged quantity does not present any significant potential for abuse; or (2) contains either a narcotic or non-narcotic controlled substance and one or more adulterating or denaturing agents in such a manner, combination, quantity, proportion, or concentration that the preparation or mixture does not present any potential for abuse and, if the preparation or mixture contains a narcotic controlled substance, is formulated in such a manner that it incorporates methods of denaturing or other means so that the preparation or mixture is not liable to be abused or have ill effects, if abused, and so that the narcotic substance cannot in practice be removed.

Accordingly, pursuant to 21 U.S.C. 811(g)(3)(B), 21 CFR 1308.23, and 21 CFR 1308.24, the Assistant Administrator has determined that each of the chemical preparations or mixtures generally described in Chart I below and specifically described in the application materials received by DEA is exempt, to the extent described in 21 CFR 1308.24,

from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 (21 U.S.C. 822–823, 825–829, and 952–954) of the CSA, and 21 CFR 1301.74, as of the date that was provided in the approval letters to the individual requesters.

Scope of Approval

The exemptions are applicable only to the precise preparation or mixture described in the application submitted to DEA in the form(s) listed in this order and only for those above mentioned sections of the CSA and the CFR. In accordance with 21 CFR 1308.24(h), any change in the quantitative or qualitative composition of the preparation or mixture, or change in the trade name or other designation of the preparation or mixture after the date of application requires a new application. The requirements set forth in 21 CFR 1308.24(b)–(e) apply to the exempted materials. In accordance with 21 CFR 1308.24(g), DEA may prescribe requirements other than those set forth in 21 CFR 1308.24(b)–(e) on a case-by-case basis for materials exempted in bulk quantities. Accordingly, in order to

limit opportunity for diversion from the larger bulk quantities, DEA has determined that each of the exempted bulk products listed in this order may only be used in-house by the manufacturer, and may not be distributed for any purpose, or transported to other facilities.

Additional exempt chemical preparation requests received between September 1, 2020, and March 31, 2021, and not otherwise referenced in this order, may remain under consideration until DEA receives additional information required, pursuant to 21 CFR 1308.23(d), as detailed in separate correspondence to individual requesters. DEA's order on such requests will be communicated to the public in a future **Federal Register** publication.

DEA also notes that these exemptions are limited to exemption from only those sections of the CSA and the CFR that are specifically identified in 21 CFR 1308.24(a). All other requirements of the CSA and the CFR apply, including registration as an importer as required by 21 U.S.C. 957.

CHART I

Supplier	Product name	Form	Application date
Aalto Scientific, Ltd	Cal Ver FLQ Drugs of Abuse for Roche Systems Level 1	Glass vial: 3 mL	2/23/2021
Aalto Scientific, Ltd	Cal Ver FLQ Drugs of Abuse for Roche Systems Level 2	Glass vial: 3 mL	2/23/2021
Aalto Scientific, Ltd	Cal Ver FLQ Drugs of Abuse for Roche Systems Level 3	Glass vial: 3 mL	2/23/2021
Aalto Scientific, Ltd	Linearity FD Fertility Siemens Centaur	Kit: 10 vials; 3 mL each	3/29/2021
Aalto Scientific, Ltd	Linearity FLQ TDM for Ortho Vitros	Kit: 5 dropper bottles; 4 mL each	3/31/2021
Agilent Technologies	Custom Organic Std—11 analytes at 250 µg/mL	Amber ampule: 1 mL	2/19/2021
Cambridge Isotope Laboratories, Inc	Labeled Steroid Mix 40X Set S NSK-S-40X	Glass vial: 1 mL	3/1/2021
Cambridge Isotope Laboratories, Inc	Delta-9-tetrahydrocannabinol (THC) Unlabeled (95% CP), 1000 µg/mL in methanol (0.1%)	Glass ampule: 1.2 mL	2/19/2021
Cambridge Isotope Laboratories, Inc	Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 100 µg/mL in methanol (0.01%)	Glass ampule: 1.2 mL	2/19/2021
Cambridge Isotope Laboratories, Inc	Testosterone (2,3,4-13C3, 99%) 100 µg/mL in acetonitrile	Glass ampule: 1 mL	2/19/2021
Cayman Chemical Company	(+/-)-11-hydroxy-d8-THC (CRM) 1 mg/ml, 1 mL in acetonitrile	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	(+/-)-11-hydroxy-d8-THC (CRM) 1 mg/ml, 1 mL in methanol	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	(+/-)-11-hydroxy-d8-THC (CRM) 100 µg/mL, 1 mL in acetonitrile	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	(+/-)-11-hydroxy-d8-THC (CRM) 100 µg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	Benzoyllecgonine (CRM) 1 mg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Benzoyllecgonine (CRM) 100 µg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Benzoyllecgonine-d3 (CRM) 1 mg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Benzoyllecgonine-d3 (CRM) 100 µg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Cocaine-d3 (CRM) 1 mg/mL, 1 mL in acetonitrile	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Cocaine-d3 (CRM) 100 µg/mL, 1 mL in acetonitrile	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	D8-THCB (CRM) 100 µg/mL, 1 mL acetonitrile	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	D8-THCB (CRM) 1 mg/ml, 1 mL in acetonitrile	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	D8-THCB (CRM) 1 mg/ml, 1 mL methanol	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	D8-THCB (CRM) 100 µg/mL, 1 mL methanol	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	D8-THCP (CRM) 1 mg/ml, 1 mL in acetonitrile	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	D8-THCP (CRM) 1 mg/ml, 1 mL methanol	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	D8-THCP (CRM) 100 µg/mL, 1 mL acetonitrile	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	D8-THCP (CRM) 100 µg/mL, 1 mL methanol	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	D9-THC Acetate (CRM) 1 mg/mL, 1 mL in acetonitrile	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	D9-THC Acetate (CRM) 1 mg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	D9-THC Acetate (CRM) 100 µg/mL, 1 mL in acetonitrile	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	D9-THC Acetate (CRM) 100 µg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Norfentanyl-d5 (CRM) 1 mg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Norfentanyl-d5 (CRM) 100 µg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 5 (CRM) 100 µg/mL 0.5 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 0.5 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 5 (CRM) 100 µg/mL 0.5 mL in acetonitrile.	Glass ampule: 0.5 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 1 mg/mL 0.5 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 0.5 mL	2/23/2021

CHART I—Continued

Supplier	Product name	Form	Application date
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 1 mg/mL 0.5 mL in acetonitrile	Glass ampule: 0.5 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 1 mg/mL 1 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 1 mg/mL 1 mL in acetonitrile	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 100 µg/mL 1 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 100 µg/mL 1 mL in acetonitrile	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 250 µg/mL 0.5 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 0.5 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 250 µg/mL 0.5 mL in acetonitrile.	Glass ampule: 0.5 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 250 µg/mL 1 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 250 µg/mL 1 mL in acetonitrile	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 500 µg/mL 0.5 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 0.5 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 500 µg/mL 0.5 mL in acetonitrile.	Glass ampule: 0.5 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 500 µg/mL 1 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 500 µg/mL 1 mL in acetonitrile	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 1 mg/mL 0.5 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 0.5 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 6 (CRM) 1 mg/mL, 1 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 1 mg/mL, 1 mL in acetonitrile	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 100 µg/mL 0.5 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 0.5 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 100 µg/mL 0.5 mL in acetonitrile.	Glass ampule: 0.5 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 100 µg/mL, 1 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 100 µg/mL, 1 mL in acetonitrile.	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 250 µg/mL 0.5 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 0.5 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 250 µg/mL 0.5 mL in acetonitrile.	Glass ampule: 0.5 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 250 µg/mL, 1 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 250 µg/mL, 1 mL in acetonitrile.	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 500 µg/mL, 1 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 500 µg/mL, 1 mL in acetonitrile.	Glass ampule: 1 mL	2/3/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 500 µg/mL 0.5 mL in 1:99 DIPEA: acetonitrile with 0.05% ascorbic acid.	Glass ampule: 0.5 mL	2/23/2021
Cayman Chemical Company	Phytocannabinoid Acids Mixture 7 (CRM) 500 µg/mL 0.5 mL in acetonitrile.	Glass ampule: 0.5 mL	2/3/2021
Cayman Chemical Company	Psilocin (CRM) 1 mg/mL in Acetonitrile	Glass ampule: 1.0 mL	2/24/2021
Cayman Chemical Company	Psilocin (CRM) 100 µg/mL in Acetonitrile	Glass ampule: 0.5 mL	2/24/2021
Cayman Chemical Company	Psilocin-d10 (CRM) 1 mg/mL in Acetonitrile	Glass ampule: 1.0 mL	2/24/2021
Cayman Chemical Company	Psilocin-d10 (CRM) 100 µg/mL in Acetonitrile	Glass ampule: 1.0 mL	2/24/2021
Cayman Chemical Company	Psilocin-d4 (CRM) 1 mg/mL in Acetonitrile	Glass ampule: 1.0 mL	2/24/2021
Cayman Chemical Company	Psilocin-d4 (CRM) 100 µg/mL in Acetonitrile	Glass ampule: 1.0 mL	2/24/2021
Cayman Chemical Company	Psilocybin (CRM) 1 mg/mL in 1:1 Acetonitrile:H2O	Glass ampule: 1.0 mL	2/24/2021
Cayman Chemical Company	Psilocybin (CRM) 100 µg/mL in 1:1 Acetonitrile:H2O	Glass ampule: 0.5 mL	2/24/2021
Cayman Chemical Company	Psilocybin-d10 (CRM) 1 mg/mL in 1:1 Acetonitrile:H2O	Glass ampule: 1.0 mL	2/24/2021
Cayman Chemical Company	Psilocybin-d10 (CRM) 100 µg/mL in 1:1 Acetonitrile:H2O	Glass ampule: 1.0 mL	2/24/2021
Cayman Chemical Company	Psilocybin-d4 (CRM) 1 mg/mL in 1:1 Acetonitrile:H2O	Glass ampule: 0.5 mL	2/24/2021
Cayman Chemical Company	Psilocybin-d4 (CRM) 100 µg/mL in 1:1 Acetonitrile:H2O	Glass ampule: 0.5 mL	2/24/2021
Cayman Chemical Company	U-47700 (CRM) 1 mg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	U-47700 (CRM) 100 µg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	U-47700-d6 (CRM) 1 mg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/23/2021
Cayman Chemical Company	U-47700-d6 (CRM) 100 µg/mL, 1 mL in methanol	Glass ampule: 1 mL	2/23/2021
Cerilliant Corporation	(-)-delta8-THC-D3	Glass ampule: 1 mL	1/26/2021
Cerilliant Corporation	4-Methyl-alpha-pyrrolidinobutophenone HCl (MPBP HCl) (1.0 mg/mL)	Glass ampule: 1 mL	3/4/2021
Cerilliant Corporation	Tetrahydrocannabivarin-D5 (THCV-D5)	Glass ampule: 1 mL	1/26/2021
Cerilliant Corporation	Tetrahydrocannabivarinic acid-D5 (THCVA-D5)	Glass ampule: 1 mL	1/26/2021
Immunalysis Corporation	AMP/6-AM Oral Fluid Calibrator 1	Amber vial: 10 mL	2/10/2021
Immunalysis Corporation	AMP/6-AM Oral Fluid Calibrator 2	Amber vial: 10 mL	2/10/2021
Immunalysis Corporation	AMP/6-AM Oral Fluid Calibrator 3	Amber vial: 10 mL	2/10/2021
Immunalysis Corporation	AMP/6-AM Oral Fluid Calibrator 4	Amber vial: 10 mL	2/10/2021
Immunalysis Corporation	AMP/6-AM Oral Fluid Set	Kit: 2 vials, 10 mL each	2/10/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 202 Kit 250 µg/mL in Acetonitrile	1 kit: 2 vials × 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 203 Kit 500 µg/mL in Acetonitrile	1 kit: 2 vials × 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 204 Kit 1000 µg/mL in Acetonitrile	1 kit: 2 vials × 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 205 Kit 250 µg/mL in Acetonitrile	1 kit: 2 vials × 0.4 mL	3/19/2021

CHART I—Continued

Supplier	Product name	Form	Application date
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 206 Kit 500 µg/mL in Acetonitrile	1 kit: 2 vials × 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 207 Kit 1000 µg/mL in Acetonitrile	1 kit: 2 vials × 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 214 Kit 250 µg/mL in Acetonitrile	1 kit: 2 vials × 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 214 Kit 250 µg/mL in Acetonitrile	1 Kit: 2 vials × 0.4 mL	10/9/2020
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 215 Kit 500 µg/mL in Acetonitrile	1 kit: 2 vials × 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 215 Kit 500 µg/mL in Acetonitrile	1 Kit: 2 vials × 0.4 mL	10/9/2020
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 216 Kit 1000 µg/mL in Acetonitrile	1 kit: 2 vials × 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 216 Kit 1000 µg/mL in Acetonitrile	1 Kit: 2 vials × 0.4 mL	10/9/2020
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 250 Kit 1000 µg/mL in Acetonitrile	1 kit: 2 vials × 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acid/Neutrals Mixture 250 Kit 1000 µg/mL in Acetonitrile	1 Kit: 2 vials × 0.4 mL	10/9/2020
LGC—Dr. Ehrenstorfer	Cannabinoids Acids Mixture 184 1000 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acids Mixture 185 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acids Mixture 186 250 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acids Mixture 194 250 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acids Mixture 195 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acids Mixture 195 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acids Mixture 210 250 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acids Mixture 210 250 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	10/9/2020
LGC—Dr. Ehrenstorfer	Cannabinoids Acids Mixture 211 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acids Mixture 211 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	10/9/2020
LGC—Dr. Ehrenstorfer	Cannabinoids Acids Mixture 212 1000 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Acids Mixture 212 1000 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	10/9/2020
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 187 100 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 188 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 189 1000 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 190 50 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 191 100 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 192 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 193 1000 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 197 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 198 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 213 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 254 250 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 254 250 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	10/9/2020
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 255 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 255 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	10/9/2020
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 256 250 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 256 250 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/10/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 257 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 257 500 µg/mL in Acetonitrile	Amber ampule: 0.4 mL	3/10/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 258 Kit 250 µg/mL in Acetonitrile	1 kit: 2 vials × 0.4 mL	3/31/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 258 Kit 250 µg/mL in Acetonitrile	1 Kit: 2 vials × 0.4 mL	3/10/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 259 Kit 500 µg/mL in Acetonitrile	1 kit: 2 vials × 0.4 mL	3/19/2021
LGC—Dr. Ehrenstorfer	Cannabinoids Mixture 259 Kit 500 µg/mL in Acetonitrile	1 Kit: 2 vials × 0.4 mL	3/10/2021
LGC—Dr. Ehrenstorfer	Custom Δ9-Tetrahydrocannabinavarin (THCV) 1000 ug/mL in Acetonitrile	Amber ampule: 1 mL	1/19/2021
LGC—Dr. Ehrenstorfer	Δ9-Tetrahydrocannabinavarinic acid (THCVA) 100 ug/mL in Acetonitrile	Amber ampule: 1 mL	3/10/2021
o2si smart solutions	Chloral Hydrate 1000 µg/mL in methanol	Amber ampule: 1 mL	3/24/2021
o2si smart solutions	Custom Pharmaceutical Mixture CCV 16–0260, 10.0 µg/mL, 300 µL with a 2 mL silanized vial (ISO17034).	Amber ampule: 300 µL	3/1/2021
o2si smart solutions	Custom Pharmaceutical Mixture ICV (second source), 16–0260, 10.0 µg/mL, 300 µL with a 2 mL silanized vial (ISO17034).	Amber ampule: 300 µL	3/1/2021
o2si smart solutions	Custom Pharmaceutical Mixture Level #1, 16–0260, 0.3 µg/mL, 300 µL with a 2 mL silanized vial (ISO17034).	Amber ampule: 300 µL	3/1/2021
o2si smart solutions	Custom Pharmaceutical Mixture Level #2, 16–0260, 1.0 µg/mL, 300 µL with a 2 mL silanized vial (ISO17034).	Amber ampule: 300 µL	3/1/2021
o2si smart solutions	Custom Pharmaceutical Mixture Level #3, 16–0260, 5.0 µg/mL, 300 µL with a 2 mL silanized vial (ISO17034).	Amber ampule: 300 µL	3/1/2021
o2si smart solutions	Custom Pharmaceutical Mixture Level #4, 16–0260, 10.0 µg/mL, 300 µL with a 2 mL silanized vial (ISO17034).	Amber ampule: 300 µL	3/1/2021
o2si smart solutions	Custom Pharmaceutical Mixture Level #5, 16–0260, 25.0 µg/mL, 300 µL with a 2 mL silanized vial (ISO17034).	Amber ampule: 300 µL	3/1/2021
o2si smart solutions	Custom Pharmaceutical Mixture Level #6, 16–0260, 50.0 µg/mL, 300 µL with a 2 mL silanized vial (ISO17034).	Amber ampule: 300 µL	3/1/2021
o2si smart solutions	Custom Pharmaceutical Mixture Level #7, 16–0260, 100.0 µg/mL, 300 µL with a 2 mL silanized vial (ISO17034).	Amber ampule: 300 µL	3/1/2021
o2si smart solutions	Custom Pharmaceutical Mixture Level #8, 16–0260, 250.0 µg/mL, 300 µL with a 2 mL silanized vial (ISO17034).	Amber ampule: 300 µL	3/1/2021
o2si smart solutions	Custom Pharmaceutical Mixture Calibration Kit 16–0260, (2 × G34–140260–98).	1 kit: 26 amber ampules × 300 µL	3/1/2021
o2si smart solutions	Custom Pharmaceutical Mixture Calibration Pack 16–0260, 13 × 1 ml	1 pack; 13 amber ampules × 300 µL	3/1/2021
o2si smart solutions	Custom Pharmaceutical Mixture LCS, 16–0260, 10.0 ug/mL, 1 mL with a 2 ml Silanized Vial (ISO17034).	Amber ampule: 1 mL	3/1/2021
Research Triangle Institute	0584, 7232, 6089, 8785, 7227, 8588, 7541, 4336, 1817, 0737, 5340, 2985, 8470, 3501, 7362, 6850, 5497, 4097, 2479, 1536, 7431, 9541, 1585, 8534, 2113, 9789, 2482, 1013, 1483, 8092, 6365, 2209, 5434, 4035, 9222, 9674, 5622, 3806, 1798, 9820.	HDPE tubes: 5 mL	3/11/2021
Research Triangle Institute	3370, 1411, 5883, 5713, 8800, 3630, 8683, 4541, 8161, 0359, 9704, 2184, 0341, 2901, 0790, 6548, 3466, 0352, 5288, 8594, 0279, 8762, 3687, 2819, 8743, 7197, 5064, 0199, 1609, 8643, 6467, 2245, 0706, 0147, 6876, 3732, 9314, 1059, 8245, 8685.	HDPE tubes: 5 mL	3/11/2021

CHART I—Continued

Supplier	Product name	Form	Application date
Research Triangle Institute	4118, 3472, 9120, 3742, 9323, 4475, 5116, 7455, 3780, 9052, 4910, 2630, 6141, 9351, 5220, 2730, 6408, 3560, 4063, 0427, 0669, 8350, 9163, 6359, 0113, 1893, 4552, 2951, 1357, 8372, 9203, 3150, 9587, 9290, 4399, 2454, 2468, 7560, 6645, 8756.	HDPE tubes: 5 mL	3/11/2021
Research Triangle Institute	4761, 2869, 4267, 9207, 1568, 8723, 7042, 6810, 0605, 7181, 8624, 0015, 5050, 7046, 3626, 7515, 9023, 8821, 6767, 0861, 0689, 5934, 2105, 2006, 1040, 5645, 2749, 7908, 9154, 8450, 5251, 6608, 3152, 9027, 2731, 7530, 1329, 0320, 5833, 7580.	HDPE tubes: 5 mL	3/11/2021
Research Triangle Institute	4946, 2135, 7589, 456, 2617, 2224, 5066, 4134, 9514, 0206, 2691, 2807, 1571, 2201, 0943, 6995, 1299, 3729, 9561, 2552, 1248, 7138, 1634, 0813, 6352, 3567, 2017, 6701, 6915, 4448, 1967, 3179, 2480, 5144, 8826, 5515, 0949, 6109, 4040, 8632.	HDPE tubes: 5 mL	3/11/2021
Research Triangle Institute	6673, 1920, 9080, 9040, 1769, 9824, 8015, 4813, 1535, 4285, 5824, 7430, 3338, 2989, 2743, 1537, 6009, 4808, 0243, 7097, 5533, 6638, 3414, 8238, 2573, 6806, 3959, 7896, 3448, 5652, 5273, 1341, 1063, 6664, 9471, 7136, 3571, 8916, 8617, 8946.	HDPE tubes: 5 mL	3/11/2021
Research Triangle Institute	7155, 9763, 5721, 5161, 0009, 8118, 7420, 0527, 4415, 6892, 6896, 8988, 6477, 9903, 6688, 0292, 9380, 4579, 9601, 7337, 1518, 2189, 8886, 8880, 6963, 9446, 7721, 9988, 7688, 2525, 4017, 6826, 3426, 4128, 6270, 4207, 0646, 5741, 6086, 0528.	HDPE tubes: 5 mL	3/11/2021
Research Triangle Institute	7938, 8287, 2990, 7693, 6858, 5995, 1929, 3740, 4461, 0196, 4271, 9853, 5024, 6378, 3409, 2702, 7629, 6194, 4553, 2871, 0203, 4812, 7073, 0834, 2732, 1841, 9545, 5063, 5062, 6234, 0210, 9740, 9472, 9938, 5122, 8677, 3537, 5198, 5977, 8203.	HDPE tubes: 5 mL	3/11/2021
Research Triangle Institute	8497, 8384, 3406, 0324, 6930, 3165, 1564, 8858, 4968, 8840, 7836, 9412, 9009, 0109, 0695, 0923, 0912, 3228, 6855, 5103, 8580, 4499, 8347, 7831, 8420, 2875, 6778, 6680, 9098, 1987, 6813, 6572, 9943, 6165, 0958, 5884, 1843, 2991, 3191, 1151.	HDPE tubes: 5 mL	3/11/2021
Research Triangle Institute	9493, 8564, 6768, 1670, 2733, 0560, 7822, 7495, 1290, 4534, 6583, 3937, 6596, 2599, 9164, 5702, 8328, 9643, 5747, 1923, 0976, 3416, 1445, 3834, 3069, 7609, 6580, 3945, 1726, 2891, 4325, 8970, 7248, 1981, 3906, 0989, 3648, 7769, 4122, 9050.	HDPE tubes: 5 mL	3/11/2021
Restek Corporation	Cannabinoids Acids 7 Standard	Glass ampule: 1.3 mL	3/31/2021
UTAK Laboratories, Inc	AED II MR Serum Control	Kit: 5 bottles, 5 mL each	11/20/2020
UTAK Laboratories, Inc	Amphetamines Panel Level 1 Urine Control	Kit: 5 bottles, 5 mL each	11/20/2020
UTAK Laboratories, Inc	Amphetamines Panel Level 2 Urine Control	Kit: 5 bottles, 5 mL each	11/20/2020
UTAK Laboratories, Inc	Benzodiazepines Hydrolysis QC Urine Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	Benzodiazepines Plus 100 ng/mL Urine Control	Kit: 5 bottles, 5 mL each	11/20/2020
UTAK Laboratories, Inc	Benzodiazepines Plus 100 ng/mL Whole Blood Control	Kit: 5 bottles, 5 mL each	11/20/2020
UTAK Laboratories, Inc	Benzodiazepines Plus 400 ng/mL Urine Control	Kit: 5 bottles, 5 mL each	11/20/2020
UTAK Laboratories, Inc	DAU IA 1 Urine Control	Kit: 4 bottles, 10 mL each	11/20/2020
UTAK Laboratories, Inc	DAU IA 2 Urine Control	Kit: 4 bottles, 10 mL each	11/20/2020
UTAK Laboratories, Inc	DAU IA 3 Urine Control	Kit: 4 bottles, 10 mL each	11/20/2020
UTAK Laboratories, Inc	DAU IA 4 Urine Control	Kit: 4 bottles, 10 mL each	11/20/2020
UTAK Laboratories, Inc	DAU IA 5 Urine Control	Kit: 4 bottles, 10 mL each	11/20/2020
UTAK Laboratories, Inc	DHEA Plus High Serum Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	DHEA Plus Low Serum Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	Drugs of Abuse 200% Cutoff SMX Oral Fluid Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	Drugs of Abuse 50% Cutoff SMX Oral Fluid Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	Drugs of Abuse Cutoff SMX Oral Fluid Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	Drugs of Abuse Level 2 Whole Blood Control	Kit: 5 bottles, 5 mL each	11/20/2020
UTAK Laboratories, Inc	Miscellaneous Panel Level 1 Urine Control	Kit: 5 bottles, 5 mL each	11/20/2020
UTAK Laboratories, Inc	Miscellaneous Panel Level 2 Urine Control	Kit: 5 bottles, 5 mL each	11/20/2020
UTAK Laboratories, Inc	Opiates Hydrolysis QC Urine Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	Pentobarbital Serum Control	Kit: 5 bottles, 5 mL each	11/20/2020
UTAK Laboratories, Inc	STABBS Negative Serum Control	Kit: 5 bottles, 5 mL each	11/20/2020
UTAK Laboratories, Inc	STABBS Positive Serum Control	Kit: 5 bottles, 5 mL each	11/20/2020
UTAK Laboratories, Inc	Steroids Level 1 SMX Serum Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	Steroids Level 2 SMX Serum Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	Steroids Level 3 SMX Serum Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	Steroids Level 4 SMX Serum Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	Tapentadol Hydrolysis QC Urine Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	Urine Drug Screen Urine Control	Kit: 5 bottles, 10 mL each	11/20/2020
UTAK Laboratories, Inc	Z Drugs Plus Level 1 Urine Control	Kit: 5 bottles, 3 mL each	11/20/2020
UTAK Laboratories, Inc	Z Drugs Plus Level 2 Urine Control	Kit: 5 bottles, 3 mL each	11/20/2020
Xvivo Perfusion	Supplemented XVIVO Heart Solution (SXHS)	Glass vial: 10 mL	9/11/2020
Xvivo Perfusion	XVIVO Heart Perfusion System (XHPS)	Kit: Heart Box, Disposable, Supplemented Soln.	9/11/2020

The Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart II below is not consistent with the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23. Accordingly, the

Assistant Administrator has determined that the chemical preparations or mixtures generally described in Chart II below and specifically described in the application materials received by DEA, are not exempt from application of any

part of the CSA or from application of any part of the CFR, with regard to the requested exemption pursuant to 21 CFR 1308.23, as of the date that was provided in the determination letters to the individual requesters.

CHART II

Supplier	Product name	Form	Application date
Cambridge Isotopes Laboratories, Inc.	Delta-9-tetrahydrocannabinol (THC) unlabeled (Chemical Purity 95%), 5 mg.	Glass ampule: 5 mg	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-tetrahydrocannabinol (THC) unlabeled (Chemical Purity 95%), 0.5 mg.	Glass ampule: 0.5 mg	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-tetrahydrocannabinol (THC) unlabeled (Chemical Purity 95%), 1 mg.	Glass ampule: 1 mg	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-tetrahydrocannabinol (THC) unlabeled (Chemical Purity 95%), 10 mg.	Glass ampule: 10 mg	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 5 mg	Glass ampule: 5 mg	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 0.5 mg	Glass ampule: 0.5 mg	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 1 mg	Glass ampule: 1 mg	2/19/2021
Cambridge Isotopes Laboratories, Inc.	Delta-9-Trans-tetrahydrocannabinol (THC) (Methyl-D3, 98%), 10 mg	Glass ampule: 10 mg	2/19/2021
Cayman Chemical Company	Clonazepam (CRM) 1 mg/mL, 1 mL in acetonitrile	Glass ampule: 1 mL	2/23/2021
LGC—Dr. Ehrenstorfer	Δ9-Tetrahydrocannabivarin 10,000 mg/L Parent stock in Methanol—NOT FOR SALE.	Boston Round, Amber glass: 14 mL	1/19/2021
LGC—Dr. Ehrenstorfer	Delta-9-THC 10000 µg/mL in Methanol	Amber ampule: 2 mL	2/16/2021

Opportunity for Comment

Pursuant to 21 CFR 1308.23(e), any interested person may submit written comments on or objections to any chemical preparation in this order that has been approved or denied as exempt. If any comments or objections raise significant issues regarding any finding of fact or conclusion of law upon which this order is based, the Assistant Administrator will immediately suspend the effectiveness of any applicable part of this order until he may reconsider the application in light of the comments and objections filed. Thereafter, the Assistant Administrator shall reinstate, revoke, or amend his original order as he determines appropriate.

Approved Exempt Chemical Preparations Are Posted on the DEA’s Website

A list of all current exemptions, including those listed in this order, is available on the DEA’s website at http://www.DEAdiversion.usdoj.gov/schedules/exempt/exempt_chemlist.pdf. The dates of applications of all current exemptions are posted for easy reference.

William T. McDermott,
Assistant Administrator.

[FR Doc. 2021–15024 Filed 7–21–21; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Parole Commission

Sunshine Act Meeting

Record of Vote of Meeting Closure

(Public Law 94–409) (5 U.S.C. Sec. 552b)

I, Patricia K. Cushwa, Acting Chairman of the United States Parole Commission, was present at a meeting of said Commission, which started at approximately 2:30 p.m., on Tuesday, July 13, 2021, at the U.S. Parole Commission, 90 K Street NE, Third Floor, Washington, DC 20530. The purpose of the meeting was to discuss an original jurisdiction case pursuant to 28 CFR 2.25. and 28 CFR 2.68(i)(1) Two Commissioners were present, constituting a quorum when the vote to close the meeting was submitted.

Public announcement further describing the subject matter of the meeting and certifications of the General Counsel that this meeting may be closed by votes of the Commissioners present were submitted to the Commissioners prior to the conduct of any other business. Upon motion duly made, seconded, and carried, the following Commissioners voted that the meeting be closed: Patricia K. Cushwa and Charles T. Massarone.

In witness whereof, I make this official record of the vote taken to close this meeting and authorize this record to be made available to the public.

Patricia K. Cushwa,
Acting Chairman, U.S. Parole Commission.

[FR Doc. 2021–15788 Filed 7–20–21; 4:15 pm]

BILLING CODE 4410–31–P

SECURITIES AND EXCHANGE COMMISSION

[Investment Company Act Release No. 34333; 812–15219]

Capital Southwest Corporation, et al.; Notice of Application

July 16, 2021.

AGENCY: Securities and Exchange Commission (“Commission”).

ACTION: Notice.

Notice of an application for an order under section 6(c) of the Investment Company Act of 1940 (the “Act”) for an exemption from sections 18(a) and 61(a) of the Act.

APPLICANTS: Capital Southwest Corporation (the “Company”), Capital Southwest SBIC I, LP (the “Capital Southwest SBIC”), and Capital Southwest SBIC I GP, LLC (the “SBIC GP”).

SUMMARY OF THE APPLICATION: The Company requests an order to permit it to adhere to a modified asset coverage requirement.

FILING DATES: The application was filed on April 21, 2021, and amended on July 14, 2021.

HEARING OR NOTIFICATION OF HEARING: An order granting the requested relief will be issued unless the Commission orders a hearing. Interested persons may request a hearing by emailing the Commission’s Secretary at Secretarys-Office@sec.gov and serving applicants with a copy of the request by email. Hearing requests should be received by the Commission by 5:30 p.m. on August 10, 2021, and should be accompanied by proof of service on applicants, in the form of an affidavit or, for lawyers, a certificate of service. Pursuant to rule 0–